
IART Stock Forecast & Price Target
IART Analyst Ratings
Bulls say
Integra Lifesciences is attractive because its core businesses are showing resilience even amid near-term disruption, with Specialty Surgical posting solid Neurosurgery growth of 7% y/y organically and strong momentum in CereLink, Certas Plus, Bactiseal, and DuraSeal. Cash generation has also improved sharply, as 3Q operating cash flow reached a record $96M and free cash flow was $86M, enabling $46M of debt repayment and reducing leverage to 3.8x from 4.1x at 2Q. The completed $2.1B refinancing extends maturities, adds covenant headroom, and supports a deleveraging-first strategy, while the stock still trades at a steep discount at about 5x P/E on the 2027 EPS estimate of $2.37.
Bears say
Integra Lifesciences is viewed cautiously because its latest quarter and FY26 guide still point to disrupted operations, with Cincinnati flood losses, lingering product ship-hold and recall effects, and slightly higher interest expense pressuring the model. Management reiterated FY26 revenue of $1.634-1.654B and adj. EPS of $2.30-2.40, but gross margin is expected to be flat versus 2025 at roughly 61.3% and about 180 bps below prior levels, underscoring weaker profitability. Although 2026-27 growth catalysts exist, the outlook remains negative because share recapture, customer re-adoption, and execution risk remain uncertain, while peers trade at meaningfully higher EV/EBITDA multiples.
This aggregate rating is based on analysts' research of Integra LifeSciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
IART Analyst Forecast & Price Prediction
Start investing in IART
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Integra LifeSciences Holdings (IART) Forecast
IART Analyst Forecast & Price Prediction
Start investing in IART
Order type
Buy in
Order amount
Est. shares
0 shares